Sellas Life Sciences Group Inc. – Capital Raise Amid Breakthrough AML Vaccine Data
Sellas Life Sciences Group Inc. (NASDAQ: SLS), a New York‑based biotechnology company focused on late‑stage oncology therapeutics, announced on 17 November 2026 that it will conduct a $150 million underwritten public offering. The announcement, reported by Investing.com, GlobeNewswire, and CEO.ca, follows a landmark clinical success for the company’s lead asset, galinpepimut‑S (GPS), an off‑the‑shelf cancer vaccine targeting acute myeloid leukemia (AML).
Vaccine Milestone and Market Impact
Bloomberg reported that GPS achieved a 41 % reduction in mortality versus the best available treatment, with a median overall survival of 24 months compared to less than 15 months for standard therapies. The data were generated in a phase‑III trial and led to a 233 % intraday rally in Sellas shares, the largest single‑day gain on record for the stock. Analyst James Molloy of Alliance Global Partners noted that the results “could usher in a new treatment option” for AML patients and, if approved, position GPS as a potential standard of care.
The announcement has also amplified investor enthusiasm, as reflected in coverage on Invezz.com that highlighted the over 220 % surge in share price. Short interest had previously climbed to 29 % of freely tradable shares, underscoring a notable shift in market sentiment following the data release.
Financing Strategy and Capital Deployment
The $150 million offering is intended to provide Sellas with the resources needed to:
- Advance regulatory submissions for GPS in the United States and internationally.
- Scale up manufacturing to meet projected commercial demand.
- Support the development of additional pipeline candidates within the company’s oncology portfolio.
Given the company’s market cap of approximately $1.52 billion and a trailing close price of $7.47 on 15 November 2026, the offering represents a significant capital infusion that will likely dilute existing shareholders but is expected to underpin long‑term growth.
Financial Position and Outlook
With a price‑earnings ratio of –38.39, Sellas remains a high‑growth, pre‑profit entity. The recent trial success, however, has sharpened expectations for a near‑term shift toward positive earnings as the company moves closer to product launch. The stock’s 52‑week range (high of $15.88 on 29 June 2026 and low of $1.39 on 1 December 2025) reflects a volatile but ultimately upward trajectory driven by clinical milestones.
Conclusion
Sellas Life Sciences Group’s timely capital raise, coupled with breakthrough data for its lead AML vaccine, positions the company at a pivotal juncture. The infusion of $150 million will accelerate regulatory and commercial milestones, potentially transforming GPS from a clinical success into a revenue‑generating therapy. Market participants are watching closely as the company navigates the next phases of development and commercialization, with the potential to redefine treatment paradigms for acute myeloid leukemia.




